Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Chagas Disease (American Trypanosomiasis) - Overview
Chagas Disease (American Trypanosomiasis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Chagas Disease (American Trypanosomiasis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Chagas Disease (American Trypanosomiasis) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Cesa Alliance SA
Collaborations Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Diakonos Research Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
IC-MedTech Inc
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Selva Therapeutics Inc
Synstar Japan Co Ltd
Chagas Disease (American Trypanosomiasis) - Drug Profiles
(benznidazole + pyroridine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(sodium ascorbate + medione sodium bisulfite) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease (bivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas disease vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cz-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-121 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DNDI-0690 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fexinidazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fosravucozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNF-6702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
K-777 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MAO-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyroridine tetraphosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLV-213 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for African Trypanosomiasis and Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Protozoal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cruzipain for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP51A1 for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Pex14 for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VNI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Chagas Disease (American Trypanosomiasis) - Dormant Projects
Chagas Disease (American Trypanosomiasis) - Discontinued Products
Chagas Disease (American Trypanosomiasis) - Product Development Milestones
Featured News & Press Releases
Jun 01, 2019: Vaccine for prevention and treatment of Trypanosoma cruzi infection
Jun 22, 2017: UTEP Scientists Awarded Patent for Chagas Disease Vaccine
Aug 08, 2016: A single compound could treat three parasitic diseases
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy
May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease
Mar 12, 2012: DNDi Receives ?2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development for Chagas Disease (American Trypanosomiasis), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Products under Development by Universities/Institutes, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by AstraZeneca Plc, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Cesa Alliance SA, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Daiichi Sankyo Co Ltd, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Diakonos Research Ltd, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Eisai Co Ltd, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by GlaxoSmithKline Plc, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by IC-MedTech Inc, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Novartis AG, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Oblita Therapeutics BVBA, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Sanofi, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Selva Therapeutics Inc, H2 2020
Chagas Disease (American Trypanosomiasis) - Pipeline by Synstar Japan Co Ltd, H2 2020
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2020
Chagas Disease (American Trypanosomiasis) - Dormant Projects, H2 2020 (Contd..1), H2 2020
Chagas Disease (American Trypanosomiasis) - Discontinued Products, H2 2020